Patents by Inventor Nathan Trinklein

Nathan Trinklein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-BCMA heavy chain-only antibodies
    Patent number: 11970540
    Abstract: Anti-BCMA heavy chain-only antibodies (UniAb) and disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat B-cell disorders characterized by the expression of BCMA.
    Type: Grant
    Filed: June 20, 2018
    Date of Patent: April 30, 2024
    Assignee: TENEOBIO, INC.
    Inventors: Nathan Trinklein, Shelley Force Aldred, Katherine Harris, Wim van Schooten
  • ANTI-PSMA ANTIBODIES AND CAR-T STRUCTURES
    Publication number: 20240131074
    Abstract: Anti-PSMA antibodies (e.g., UniAbs™) and CAR-T structures are disclosed, along with methods of making such antibodies and CAR-T structures, compositions, including pharmaceutical compositions, comprising such antibodies and CAR-T structures, and their use to treat disorders that are characterized by the expression of PSMA.
    Type: Application
    Filed: February 25, 2022
    Publication date: April 25, 2024
    Inventors: Starlynn Clarke, Brian Avanzino, Kevin Dang, Nathan Trinklein, Katherine Harris
  • ANTI-BCMA HEAVY CHAIN-ONLY ANTIBODIES
    Publication number: 20240124599
    Abstract: Anti-BCMA heavy chain-only antibodies (UniAb) and disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat B-cell disorders characterized by the expression of BCMA.
    Type: Application
    Filed: September 15, 2023
    Publication date: April 18, 2024
    Inventors: Nathan Trinklein, Shelley Force Aldred, Katherine Harris, Wim van Schooten
  • CD3-DELTA/EPSILON HETERODIMER SPECIFIC ANTIBODIES
    Publication number: 20240117050
    Abstract: Novel human CD3 antigen-binding polypeptides and their preparation and use in the treatment and/or diagnosis of various diseases are provided, as well as bispecific antibody molecules capable of activating immune effector cells and their use in diagnosis and/or treatment of various diseases.
    Type: Application
    Filed: October 12, 2023
    Publication date: April 11, 2024
    Inventors: Ute Schellenberger, Nathan Trinklein, Wim van Schooten
  • ANTI-CD20 ANTIBODIES AND CAR-T STRUCTURES
    Publication number: 20240117063
    Abstract: Ani-CD20 antibodies (e.g., UniAbs™) and CAR-T structures are disclosed, along with methods of making such antibodies and CAR-T structures, compositions, including pharmaceutical compositions, comprising such antibodies and CAR-T structures, and their use to treat disorders that are characterized by the expression of CD20.
    Type: Application
    Filed: September 25, 2023
    Publication date: April 11, 2024
    Inventors: Nathan Trinklein, Katherine Harris, Nicole Allen, Karen Chang, Brian Avanzino
  • ANTI-B-CELL MATURATION ANTIGEN CHIMERIC ANTIGEN RECEPTORS WITH HUMAN DOMAINS
    Publication number: 20240091264
    Abstract: Provided are chimeric antigen receptors (CARs) having antigen specificity for B-cell Maturation Antigen (BCMA). Also provided are related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the CARs. Methods of treating or preventing cancer in a mammal are also provided.
    Type: Application
    Filed: November 30, 2023
    Publication date: March 21, 2024
    Applicants: The United States of America, as represented by the Secretary, Dept. of Health and Human Services, TeneoBio, Inc.
    Inventors: James N. Kochenderfer, Norris Lam, Nathan Trinklein, Katherine E. Harris, Shelley Force Aldred, Wim Van Schooten
  • Multispecific heavy chain antibodies binding to CD22 and CD3
    Patent number: 11905326
    Abstract: Multispecific, human heavy chain antibodies (e.g., UniAbs™) binding to CD22 and CD3 are disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat disorders that are characterized by the expression of CD22.
    Type: Grant
    Filed: June 12, 2020
    Date of Patent: February 20, 2024
    Assignee: TeneoBio, Inc.
    Inventors: Nathan Trinklein, Udaya Rangaswamy, Suhasini Iyer, Kirthana Prabhakar, Harshad Ugamraj
  • ANTI-CD19 ANTIBODIES AND CAR-T STRUCTURES
    Publication number: 20240042032
    Abstract: Anti-CD19 antibodies (e.g., UniAbs™) and CAR-T structures are disclosed, along with methods of making such antibodies and CAR-T structures, compositions, including pharmaceutical compositions, comprising such antibodies and CAR-T structures, and their use to treat disorders that are characterized by the expression of CD19.
    Type: Application
    Filed: September 22, 2023
    Publication date: February 8, 2024
    Inventors: Nathan Trinklein, Katherine Harris, Brian Avanzino, Joseph S. Lucas, Laura Davison, Blair B. Madison, Karen Chang
  • Agonistic anti-IL-2R antibodies and methods of use
    Patent number: 11884735
    Abstract: Anti-IL2R (e.g., anti-IL2RB, anti-IL2RG, anti-IL2RB/G) antibodies are disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and use of such antibodies and compositions in the treatment of diseases and disorders that are mediated by the IL2/IL2R signaling pathway.
    Type: Grant
    Filed: February 3, 2023
    Date of Patent: January 30, 2024
    Assignee: TENEOBIO, INC.
    Inventors: Nathan Trinklein, Katherine Harris, Kyle Lorentsen, Harbani Kaur Malik Chaudhry, Kaitlyn Loughlin
  • AGONISTIC ANTI-IL-2R ANTIBODIES AND METHODS OF USE
    Publication number: 20240018250
    Abstract: Anti-IL2R (e.g., anti-IL2RB, anti-IL2RG, anti-IL2RB/G) antibodies are disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and use of such antibodies and compositions in the treatment of diseases and disorders that are mediated by the IL2/IL2R signaling pathway.
    Type: Application
    Filed: August 29, 2023
    Publication date: January 18, 2024
    Inventors: Nathan Trinklein, Katherine Harris, Kyle Lorentsen, Harbani Kaur Malik Chaudhry, Kaitlyn Loughlin
  • CD3 BINDING ANTIBODIES
    Publication number: 20240018235
    Abstract: The present invention relates to novel human CD3 antigen-binding polypeptides and their preparation and use in the treatment and/or diagnosis of various diseases, and also relates to bispecific antibody molecules capable of activating immune effector cells and their use in diagnosis and/or treatment of various diseases.
    Type: Application
    Filed: January 18, 2023
    Publication date: January 18, 2024
    Inventors: Nathan Trinklein, Wim van Schooten, Shelley Force Aldred, Katherine Harris, Duy Pham
  • HEAVY CHAIN ANTIBODIES BINDING TO FOLATE RECEPTOR ALPHA
    Publication number: 20240002498
    Abstract: Anti-Folate Receptor Alpha (FOLR1) heavy chain antibodies (e.g., UniAbs™) are disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat disorders that are characterized by the expression of Folate Receptor Alpha (FOLR1).
    Type: Application
    Filed: November 17, 2021
    Publication date: January 4, 2024
    Inventors: Brian Avanzino, Katherine Harris, Hannes Kehm, Nathan Trinklein
  • CD3 BINDING ANTIBODIES
    Publication number: 20230272075
    Abstract: The present invention relates to human CD3 antigen-binding polypeptides and their preparation and use in the treatment and/or diagnosis of various diseases, and also relates to bispecific antibody molecules capable of activating immune effector cells and their use in diagnosis and/or treatment of various diseases.
    Type: Application
    Filed: October 3, 2022
    Publication date: August 31, 2023
    Inventors: Nathan Trinklein, Wim van Schooten, Shelley Force Aldred, Katherine Harris, Duy Pham
  • MULTI-SPECIFIC ANTIBODIES BINDING TO BCMA
    Publication number: 20230257473
    Abstract: Multi-specific, human heavy chain antibodies (e.g., UniAbs™) binding to BCMA are disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat disorders that are characterized by the expression of BCMA.
    Type: Application
    Filed: June 30, 2021
    Publication date: August 17, 2023
    Inventors: Nathan Trinklein, Katherine Harris, Harbani Malik, Ute Schellenberger, Omid Vafa, Shelley Force Aldred
  • AGONISTIC ANTI-IL-2R ANTIBODIES AND METHODS OF USE
    Publication number: 20230242653
    Abstract: Anti-IL2R (e.g., anti-IL2RB, anti-IL2RG, anti-IL2RB/G) antibodies are disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and use of such antibodies and compositions in the treatment of diseases and disorders that are mediated by the IL2/IL2R signaling pathway.
    Type: Application
    Filed: February 3, 2023
    Publication date: August 3, 2023
    Inventors: Nathan Trinklein, Katherine Harris, Kyle Lorentsen, Harbani Kaur Malik Chaudhry, Kaitlyn Loughlin
  • MULTISPECIFIC HEAVY CHAIN ANTIBODIES WITH MODIFIED HEAVY CHAIN CONSTANT REGIONS
    Publication number: 20230203161
    Abstract: Multispecific, human heavy chain antibodies (e.g., UniAbs™) that have modified heavy chain constant regions that impart advantageous properties are provided. The invention further concerns methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat disorders that are characterized by expression of one or more of the binding targets described herein.
    Type: Application
    Filed: April 29, 2021
    Publication date: June 29, 2023
    Inventors: Katherine Harris, Ute Schellenberger, Omid Vafa, Nathan Trinklein, Wim Van Schoofen, Shelley Force Aldred, Duy Pham, Starlynn Clarke
  • CD3 binding antibodies
    Patent number: 11613572
    Abstract: The present invention relates to novel human CD3 antigen-binding polypeptides and their preparation and use in the treatment and/or diagnosis of various diseases, and also relates to bispecific antibody molecules capable of activating immune effector cells and their use in diagnosis and/or treatment of various diseases.
    Type: Grant
    Filed: June 20, 2017
    Date of Patent: March 28, 2023
    Assignee: TeneoBio, Inc.
    Inventors: Nathan Trinklein, Wim van Schooten, Shelley Force Aldred, Katherine Harris, Duy Pham
  • CD3 BINDING ANTIBODIES
    Publication number: 20230082151
    Abstract: The present invention relates to human CD3 antigen-binding polypeptides and their preparation and use in the treatment and/or diagnosis of various diseases, and also relates to bispecific antibody molecules capable of activating immune effector cells and their use in diagnosis and/or treatment of various diseases.
    Type: Application
    Filed: August 19, 2022
    Publication date: March 16, 2023
    Inventors: Nathan Trinklein, Wim van Schooten, Shelley Force Aldred, Katherine Harris, Duy Pham
  • ANTI-BCMA HEAVY CHAIN-ONLY ANTIBODIES
    Publication number: 20230060847
    Abstract: Anti-BCMA heavy chain-only antibodies (UniAb) and disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat B-cell disorders characterized by the expression of BCMA.
    Type: Application
    Filed: August 29, 2022
    Publication date: March 2, 2023
    Inventors: Nathan Trinklein, Shelley Force Aldred, Starlynn Clarke, Wim van Schooten
  • ANTI-BCMA HEAVY CHAIN-ONLY ANTIBODIES
    Publication number: 20230045100
    Abstract: Anti-BCMA heavy chain-only antibodies(HCAb) and disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat B-cell disorders characterized by the expression of BCMA.
    Type: Application
    Filed: June 29, 2022
    Publication date: February 9, 2023
    Inventors: Shelley Force Aldred, Nathan Trinklein, Katherine E. Harris, Kevin Dang, Wim van Schooten